巨細胞性動脈炎(GCA)の市場インサイト・疫学・市場予測(~2028)

◆英語タイトル:Giant cell arteritis (GCA) Market Insights, Epidemiology and Market Forecast-2028
◆商品コード:DATA00109021
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:147
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD6,250 ⇒換算¥718,750見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD18,750 ⇒換算¥2,156,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Giant cell arteritis (GCA) Market Insights, Epidemiology and Market Forecast-2028
DelveInsight’s ‘Giant cell arteritis (GCA) – Market Insights, Epidemiology and Market Forecast-2028′ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of GCA in the 7MM covering the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Giant cell arteritis (GCA) from 2017 to 2028 segmented by seven emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2017-2028

Giant cell arteritis (GCA) – Disease Understanding

Giant cell arteritis (GCA) is the most common form of medium and large-vessel vasculitis. Inflammation typically affects head and neck arteries, including the superficial temporal and posterior ciliary arteries. Symptoms are caused by local vascular ischemia often combined with cytokine-mediated features.

GCA remains a medical emergency because of the risk of sudden, irreversible sight loss and stroke. It is a spectrum of phenotypically overlapping conditions, including cranial GCA, extracranial GCA (otherwise termed large-vessel GCA, usually involving the aorta and its larger supra-aortic branches), and polymyalgia rheumatica (PMR).

The DelveInsight Giant cell arteritis (GCA) market report gives the thorough understanding of the Giant cell arteritis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms for Giant cell arteritis in the 7MM.

Giant cell arteritis Epidemiology

The Giant cell arteritis (GCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven countries in the report. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalence of Giant Cell Arteritis in 7MM, Sub-type specific prevalence of Giant Cell Arteritis, Gender Specific Diagnosed prevalence of Giant Cell Arteritis, Age Specific Diagnosed prevalence of Giant Cell Arteritis, Clinical Manifestations associated with Giant Cell Arteritis) scenario of Giant Cell Arteritis (GCA) in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan from 2017-2028.

According to DelveInsight, Total prevalent population of Giant Cell Arteritis in 7 MM was observed to be 423,131 cases in 2017.

Giant Cell Arteritis Drug Chapters
This segment of the Giant Cell Arteritis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Drugs that would bridge the unmet need for adjunctive therapy in order to combat the issues of side effects of GC, prolonged period of GC tapering and the risk of relapse during the tapering off cycle are being especially actively investigated.

Giant Cell Arteritis Market Outlook
The Giant Cell Arteritis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Giant Cell Arteritis in 7MM was found to be USD 862.90 Million in 2017, and is expected to increase during the course of the study period (2017-2028). United States accounts for the largest market size of Giant Cell Arteritis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Giant Cell Arteritis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Giant Cell Arteritis Report Insights

• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Giant Cell Arteritis Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake

Giant Cell Arteritis Report Assessment

• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Giant Cell Arteritis market
• Organize sales and marketing efforts by identifying the best opportunities for Giant Cell Arteritis market
• To understand the future market competition in the Giant Cell Arteritis market.

Note: We understand the needs of the rapidly changing market and DelveInsight’s is helping the client by providing the most up to date Report.

【レポートの目次】

1. Key Insights
2. Giant cell arteritis Market Overview at a Glance
2.1. Market Share (%) of Giant cell arteritis in 2017 – 7MM
2.2. Market Share (%) of Giant cell arteritis in 2028 – 7MM
3. Disease Background and Overview
3.1. Introduction
3.2. Etiology and risk factors
3.3. Signs and Symptoms associated with GCA
3.4. Pathophysiology
3.5. Clinical manifestations
3.6. Diagnosis
3.7. Molecular biomarkers in GCA patients important for diagnosis and prognosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent Cases of Giant Cell Arteritis in 7MM
5. Country Wise-Epidemiology
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalence of Giant Cell Arteritis in the United States
5.1.3. Sub-type specific prevalence of GCA in the United States
5.1.4. Gender Specific Diagnosed prevalence of GCA in the United States
5.1.5. Age Specific Diagnosed prevalence of GCA in the United States
5.1.6. Clinical Manifestations associated with GCA in the United States
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Japan
5.3.1. Assumptions and Rationale
5.3.2. Prevalence of Giant Cell Arteritis in Japan
5.3.3. Sub-type specific prevalence of GCA in Japan
5.3.4. Gender Specific Diagnosed prevalence of GCA in Japan
5.3.5. Age Specific Diagnosed prevalence of GCA in Japan
5.3.6. Clinical Manifestations associated with GCA in Japan
6. Treatment and Management
6.1. The new era for GCA: Biologic Agents
6.2. Patient Journey
7. Unmet needs
8. Case Studies
8.1. Biopsy proven giant cell arteritis in a patient with psoriatic arthritis
8.2. Delayed Diagnosis of Giant Cell Arteritis in the Setting of Isolated Lingual Necrosis.
8.3. Case Study: Giant Cell Arteritis
8.4. Case Study: Giant Cell Arteritis
8.5. Giant Cell Arteritis: A Rare Disease in Asians
9. Marketed drugs
9.1. Tocilizumab (Actemra): Genentech
9.1.1. Product Description
9.1.2. Product Development Activities
9.1.3. Clinical development
9.1.4. Safety and Efficacy
9.1.5. Product Profile
10. Emerging drugs
10.1. Key Cross Competition
10.2. KPL-301: Kiniksa Pharmaceuticals, Ltd.
10.2.1. Product Description
10.2.2. Product Development Activities
10.2.3. Clinical development
10.2.4. Clinical Trials Information
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. Upadacitinib: AbbVie
10.3.1. Product Description
10.3.2. Clinical development
10.3.3. Clinical Trials Information
10.3.4. Product Profile
10.4. Secukinumab: Novartis Pharmaceuticals
10.4.1. Product Description
10.4.2. Other Development Activities
10.4.3. Clinical Development
10.4.4. Clinical Trials Information
10.4.5. Safety and Efficacy
10.4.6. Product Profile
10.5. Sarilumab: Sanofi
10.5.1. Product Description
10.5.2. Other Developmental Activities
10.5.3. Clinical Development
10.5.4. Clinical Trials Information
10.5.5. Product Profile
11. Other products of interest
11.1. Abatacept (CTLA-4Ig)
11.1.1. Product Description
11.1.2. Clinical development
11.1.3. Clinical Trials Information
11.1.4. Safety and Efficacy
11.1.5. Product Profile
11.2. Ustekinumab
11.2.1. Product Description
11.2.2. Clinical development
11.2.3. Clinical Trials Information
11.2.4. Product Profile
12. Giant cell arteritis: 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size of Giant cell arteritis in 7MM
12.3. Market Scenario: 7MM
13. The United States Market Outlook
13.1. United States Market Size
13.1.1. Total Market size of Giant cell arteritis
13.1.2. Market Size by Therapies
14. EU-5 Countries: Market Outlook
14.1. Germany
14.1.1. Total Market size of Giant cell arteritis in Germany
14.1.2. Market Size by Therapies
14.2. France
14.2.1. Total Market Size of Giant cell arteritis
14.2.2. Market Size by Therapies
14.3. Italy
14.3.1. Total Market Size of Giant cell arteritis
14.3.2. Market Size by Therapies
14.4. Spain
14.4.1. Total Market Size of Giant cell arteritis
14.4.2. Market Size by Therapies
14.5. The United Kingdom
14.5.1. Total Market Size of Giant cell arteritis
14.5.2. Market Size by Therapies
15. Japan: Market Outlook
15.1. Japan Market Size
15.1.1. Total Market Size of Giant cell arteritis
15.1.2. Market Size by Therapies
16. Market drivers
17. Market Barriers
18. Appendix
18.1. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Table 1: Total Prevalent Population of GCA in 7MM (2017-2028)
Table 2: Prevalent Cases of GCA in the United States (2017-2028)
Table 3: Sub-type specific prevalent cases of GCA in the United States (2017-2028)
Table 4: Gender Specific Diagnosed Prevalence of GCA in the United States (2017-2028)
Table 5: Age Specific Diagnosed prevalence of GCA in the United States (2017-2028)
Table 6: Clinical Manifestations associated with GCA in the United States (2017-2028)
Table 7: Prevalent Cases of GCA in Germany (2017-2028)
Table 8: Sub-type specific prevalent cases of GCA in Germany (2017-2028)
Table 9: Gender Specific Diagnosed Prevalence of GCA in Germany (2017-2028)
Table 10: Age Specific Diagnosed prevalence of GCA in Germany (2017-2028)
Table 11: Clinical Manifestations associated with GCA in Germany (2017-2028)
Table 12: Prevalent Cases of GCA in France (2017-2028)
Table 13: Sub-type specific prevalent cases of GCA in France (2017-2028)
Table 14: Gender Specific Diagnosed Prevalence of GCA in France (2017-2028)
Table 15: Age Specific Diagnosed prevalence of GCA in France (2017-2028)
Table 16: Clinical Manifestations associated with GCA in France (2017-2028)
Table 17: Prevalent Cases of GCA in Italy (2017-2028)
Table 18: Sub-type specific prevalent cases of GCA in Italy (2017-2028)
Table 19: Gender Specific Diagnosed Prevalence of GCA in Italy (2017-2028)
Table 20: Age Specific Diagnosed prevalence of GCA in Italy (2017-2028)
Table 21: Clinical Manifestations associated with GCA in Italy (2017-2028)
Table 22: Prevalent Cases of GCA in Spain (2017-2028)
Table 23: Sub-type specific prevalent cases of GCA in Spain (2017-2028)
Table 24: Gender Specific Diagnosed Prevalence of GCA in Spain (2017-2028)
Table 25: Age Specific Diagnosed prevalence of GCA in Spain (2017-2028)
Table 26: Clinical Manifestations associated with GCA in Spain (2017-2028)
Table 27: Prevalent Cases of GCA in UK (2017-2028)
Table 28: Sub-type specific prevalent cases of GCA in UK (2017-2028)
Table 29: Gender Specific Diagnosed Prevalence of GCA in UK (2017-2028)
Table 30: Age Specific Diagnosed prevalence of GCA in UK (2017-2028)
Table 31: Clinical Manifestations associated with GCA in UK (2017-2028)
Table 32: Prevalent Cases of GCA in Japan (2017-2028)
Table 33: Sub-type specific prevalent cases of GCA in Japan (2017-2028)
Table 34: Gender Specific Diagnosed Prevalence of GCA in Japan (2017-2028)
Table 35: Age Specific Diagnosed prevalence of GCA in Japan (2017-2028)
Table 36: Clinical Manifestations associated with GCA in Japan (2017-2028)
Table 37: Tocilizumab, Clinical Trial Description, 2019
Table 38: Mavrilimumab, Clinical Trial Description, 2019
Table 39: Upadacitinib, Clinical Trial Description, 2019
Table 40: Secukinumab, Clinical Trial Description 2019
Table 41: Sarilumab, Clinical Trial Description 2019
Table 42: Abatacept, Clinical Trial Description 2019
Table 43: Upadacitinib, Clinical Trial Description, 2019
Table 44: 7 Major Market Size of Giant cell arteritis in USD Million (2017-2028)
Table 45: United States Market Size of Giant cell arteritis in the US, USD Million (2017-2028)
Table 46: Market Size of Giant cell arteritis by Therapies in the US, in USD Million (2017-2028)
Table 47: Market Size of Giant cell arteritis in Germany, in USD Million (2017-2028)
Table 48: Market Size of Giant cell arteritis by Therapies in Germany, in USD Million (2017-2028)
Table 49: Market Size of Giant cell arteritis in France, in USD Million (2017-2028)
Table 50: Market Size of Giant cell arteritis by Therapies in France, in USD Million (2017-2028)
Table 51: Market Size of Giant cell arteritis in Italy, in USD Million (2017-2028)
Table 52: Market Size of Giant cell arteritis by Therapies in Italy, in USD Million (2017-2028)
Table 53: Market Size of Giant cell arteritis in Spain, in USD Million (2017-2028)
Table 54: Market Size of Giant cell arteritis by Therapies in Spain, in USD Million (2017-2028)
Table 55: Market Size of Giant cell arteritis in the UK, in USD Million (2017-2028)
Table 56: Market Size of Giant cell arteritis by Therapies in the UK, in USD Million (2017-2028)
Table 57: Market Size of Giant cell arteritis in Japan, in USD, Million (2017-2028)
Table 58: Market Size of Giant cell arteritis by Therapies in Japan, in USD Million (2017-2028)
Figure 1: Common symptoms associated with GCA
Figure 2: Main pathways involved in the immunopathology of giant cell arteritis
Figure 3: Proposed algorithm for evaluating patients with suspected GCA
Figure 4: Total Prevalent Population of GCA in 7 MM (2017-2028)
Figure 5: Prevalent Population of GCA in the United States (2017-2028)
Figure 6: Sub-type specific prevalent cases of GCA in the United States (2017-2028)
Figure 7: Gender Specific Diagnosed Prevalence of GCA in the United States (2017-2028)
Figure 8: Age Specific Diagnosed prevalence of GCA in the United States (2017-2028)
Figure 9: Clinical Manifestations associated with GCA in the United States (2017-2028)
Figure 10: Prevalent Population of GCA in Germany (2017-2028)
Figure 11: Sub-type specific prevalent cases of GCA in Germany (2017-2028)
Figure 12: Gender Specific Diagnosed Prevalence of GCA in Germany (2017-2028)
Figure 13: Age Specific Diagnosed prevalence of GCA in Germany (2017-2028)
Figure 14: Clinical Manifestations associated with GCA in Germany (2017-2028)
Figure 15: Prevalent Population of GCA in France (2017-2028)
Figure 16: Sub-type specific prevalent cases of GCA in France (2017-2028)
Figure 17: Gender Specific Diagnosed Prevalence of GCA in France (2017-2028)
Figure 18: Age Specific Diagnosed prevalence of GCA in France (2017-2028)
Figure 19: Clinical Manifestations associated with GCA in France (2017-2028)
Figure 20: Prevalent Population of GCA in Italy (2017-2028)
Figure 21: Sub-type specific prevalent cases of GCA in Italy (2017-2028)
Figure 22: Gender Specific Diagnosed Prevalence of GCA in Italy (2017-2028)
Figure 23: Age Specific Diagnosed prevalence of GCA in Italy (2017-2028)
Figure 24: Clinical Manifestations associated with GCA in Italy (2017-2028)
Figure 25: Prevalent Population of GCA in Spain (2017-2028)
Figure 26: Sub-type specific prevalent cases of GCA in Spain (2017-2028)
Figure 27: Gender Specific Diagnosed Prevalence of GCA in Spain (2017-2028)
Figure 28: Age Specific Diagnosed prevalence of GCA in Spain (2017-2028)
Figure 29: Clinical Manifestations associated with GCA in Spain (2017-2028)
Figure 30: Prevalent Population of GCA in UK (2017-2028)
Figure 31: Sub-type specific prevalent cases of GCA in UK (2017-2028)
Figure 32: Gender Specific Diagnosed Prevalence of GCA in UK (2017-2028)
Figure 33: Age Specific Diagnosed prevalence of GCA in UK (2017-2028)
Figure 34: Clinical Manifestations associated with GCA in UK (2017-2028)
Figure 35: Prevalent Population of GCA in Japan (2017-2028)
Figure 36: Sub-type specific prevalent cases of GCA in Japan (2017-2028)
Figure 37: Gender Specific Diagnosed Prevalence of GCA in Japan (2017-2028)
Figure 38: Age Specific Diagnosed prevalence of GCA in Japan (2017-2028)
Figure 39: Clinical Manifestations associated with GCA in Japan (2017-2028)
Figure 40: Current treatment schema for GCA
Figure 41:Management of Giant Cell Arteritis (GCA)
Figure 42: Patient Journey for GCA
Figure 43: Unmet needs for GCA
Figure 44: 7 Major Market Size of Giant cell arteritis in USD Million (2017-2028)
Figure 45: 7 Major Market Size Scenario in (2017)
Figure 46: 7 Major Market Size Scenario in (2028)
Figure 45: Market Size of Giant cell arteritis in the United States, USD Millions (2017-2028)
Figure 46: Market Size of Giant cell arteritis by Therapies in the US, in USD Million (2017-2028)
Figure 47: Market Size of Giant cell arteritis in Germany, USD Million (2017-2028)
Figure 48: Market Size of Giant cell arteritis by Therapies, in Germany, in USD Million (2017-2028)
Figure 49: Market Size of Giant cell arteritis in France, USD Million (2017-2028)
Figure 50: Market Size of Giant cell arteritis by Therapies, in France, in USD Million (2017-2028)
Figure 51: Market Size of Giant cell arteritis in Italy, USD Million (2017-2028)
Figure 52: Market Size of Giant cell arteritis by Therapies in Italy, in USD Million (2017-2028)
Figure 53: Market Size of Giant cell arteritis in Spain, USD Million (2017-2028)
Figure 54: Market Size of Giant cell arteritis by Therapies in Spain, in USD Million (2017-2028)
Figure 55: Market Size of Giant cell arteritis in the UK, USD Million (2017-2028)
Figure 56: Market Size of Giant cell arteritis by Therapies in the UK, in USD Million (2017-2028)
Figure 57: Market Size of Giant cell arteritis in Japan, USD Million (2017-2028)
Figure 58: Market Size of Giant cell arteritis by Therapies in Japan, in USD Million (2017-2028)
Figure 59: Market drivers for GCA
Figure 62: Market Barriers for GCA



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[巨細胞性動脈炎(GCA)の市場インサイト・疫学・市場予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆